Literature DB >> 34607339

Luteolin attenuates hepatic injury in septic mice by regulating P2X7R-based HMGB1 release.

Zhi-Hong Zhang1,2, Hong-Xu Yang1,2, Quan Jin1,2, Yan-Ling Wu1,2, Zhen-Yu Cui1,2, Yue Shang1,2, Jian Liu1,2, Zi-Ying Zhan1,2, Li-Hua Lian1,2, Ji-Xing Nan1,2.   

Abstract

P2X7 receptor (P2X7R) and NLRP3 cooperatively participate in inflammation and hepatocyte damage during hepatic injury induced by lipopolysaccharides (LPS). High-mobility group box 1 (HMGB1) released from immune cells in response to such stimuli plays a vital role in mediating inflammation via TLR4 and the receptor for advanced glycation end products (RAGE), a receptor for HMGB1. However, the correlation among P2X7R, RAGE and TLR4 in regulating the release of HMGB1 has not been elucidated. Increasing the number of daily foods is found to be beneficial for hepatocyte damage in septic hepatic injury. Hence, we investigated the effects of luteolin, a natural flavonoid mainly existing in vegetables and fruits, on liver injury, focusing on how luteolin participates in hepatitis based on the P2X7R-RAGE-TLR4 axis by regulating the release of HMGB1. The results demonstrated that the indicators of hepatic injury such as increased ALT, AST in the serum and infiltration of immune cells were attenuated after luteolin treatment in LPS-induced mice. Luteolin could also suppress the production and release of HMGB1 and the activation of caspase 1 both in LPS-induced mice and LPS/ATP-stimulated HepG2 cells. Collectively, luteolin reversed LPS-induced hepatic injury, especially inflammation, likely by regulating the release of HMGB1 through the P2X7R-RAGE-TLR4 axis.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34607339     DOI: 10.1039/d1fo01746b

Source DB:  PubMed          Journal:  Food Funct        ISSN: 2042-6496            Impact factor:   5.396


  1 in total

1.  Luteolin Potentially Treating Prostate Cancer and COVID-19 Analyzed by the Bioinformatics Approach: Clinical Findings and Drug Targets.

Authors:  Yu Ye; Ziyan Huang; Manying Chen; Yongfeng Mo; Zengnan Mo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-01       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.